

Cell line name

RCi001-B

Purpose

The purpose of this Cell Line Information Pack (CLIP) is to communicate cell line specific information to potential users of the cell line, and to confirm that a User has received it upon the purchase of an EBiSC cell line.

Information

The CLIP may provide a variety of types of information related to an individual cell line. Of particular importance are Third Party Obligations (TPOs), which are ethical or legal obligations of a Depositor related to the use of the cell line. TPOs may impose ethical or legal limitations on the ability of a User to use the cell line, or require steps to be taken before it can be used. TPOs are likely to be:

- Obligations under license to an intellectual property rights (patent) holder, or
- Restrictions on use imposed by the donor of the primary tissue from which the cell line was made.

Third Party Obligations: donor consent provisions

Record of information provided to the donor of the primary tissue and the consent obtained

The standard terms used by the Pfizer under any research protocol are included below, which are each time independently reviewed and approved by a separate bioethics board per study.

12.2. Ethical Conduct of the Study

The study will be conducted in accordance with legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2None.None.2), Guidelines for GCP (ICH 1996), and the Declaration of Helsinki (World Medical Association 2None.None.8).

In addition, the study will be conducted in accordance with the protocol, the ICH guideline on GCP, and applicable local regulatory requirements and laws.

12.3 Informed Consent

All parties will ensure protection of subject personal data and will not include subject names or other identifiable data in any reports, publications, or other disclosures, except where required by law.

The informed consent documents must be in compliance with ICH GCP, local regulatory requirements, and legal requirements, including applicable privacy laws. The informed consent documents used during the informed consent process must be reviewed by the sponsor, approved by the IRB/EC before use, and available for inspection. The investigator must ensure that each study subject is fully informed about the nature and objectives of the study and possible risks associated with participation.

The investigator, or a person designated by the investigator, will obtain written informed consent from each subject before any study-specific activity is performed. The investigator will retain the original of each subject's signed consent document.

Third Party Obligations: IP or license provisions

iPS-AJ: This EBiSC Cell line was generated under the technology disclosed in patents related to iPS cells which are owned by Kyoto University and are licensable from iPS Academia Japan., Inc. ("iPS AJ"). Commercial user (for-profit entity) acknowledges that, prior to receipt and use of this EBiSC Cell line, such commercial user needs

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.

Cell line name

RCi001-B

to have an appropriate patent license from iPS AJ even for its research use. Academic user (academic or not-for-profit entity) acknowledges that such academic user does not need a patent license from iPS AJ for its research use, provided, however, that when such academic user uses this EBiSC Cell line for other than its independent research use, such academic user acknowledges that the academic user might need to obtain an appropriate patent license from iPS AJ. For inquiries to iPS AJ, please contact at license@ips-ac.co.jp.

Other information

Any publications or public dissemination of results using EBiSC iPSCs should be accompanied by the following acknowledgement: "The EBiSC Bank acknowledges Pfizer Ltd as the source of the human induced pluripotent cell line RCi001-B which was generated with support from the EBiSC project. The EBiSC has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking (JU) under grant agreement n°115582 and from the IMI-2 JU under grant agreement No 821362, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013), European Union's Horizon 2020 research and innovation programme and EFPIA."

SIGN AND RETURN THIS DOCUMENT WITH YOUR COMPLETED ACCESS AND USE AGREEMENT

User acknowledgement

Please sign below to indicate that you have read and acknowledge the information contained in this CLIP.

Name _____ Position _____

Signature _____ Date _____

www.EBiSC.org



In case of queries, please get in touch via: Contact@EBiSC.org.